Global Sexual Dysfunction Drugs Market Research Report 2022

Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market.
Due to the COVID-19 pandemic, the global Sexual Dysfunction Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Sexual Dysfunction Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Sexual Dysfunction Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The sexual dysfunction oral drugs segment accounted for the majority market share during 2017 and will continue to grow during the forecast period. The increasing cases of sexual dysfunctions are driving the need for oral therapies such as 5HT1A receptor agonist. The demand for sexual dysfunction oral drugs such as ED drugs will further increase due to the rising awareness among healthcare professionals.
This report focuses on Sexual Dysfunction Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Sexual Dysfunction Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Sexual Dysfunction Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by User. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Oral Therapy
Intracavernosal Therapy
Hormonal Therapy
Transurethral Therapy
Segment by User
Male
Female
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Pfizer
GlaxoSmithKline
Merck
Eli Lilly
AbbVie
Bayer
Teva Pharmaceutical Industries
Takeda
Apricus Biosciences
Emotional Brain
Ivix LLX
Leadiant Biosciences
NexMed
S1 Biopharma
Vietstar Biomedical Research